Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Large Decline in Short Interest

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) was the target of a large decrease in short interest in January. As of January 31st, there was short interest totalling 513,900 shares, a decrease of 12.5% from the January 15th total of 587,000 shares. Based on an average trading volume of 278,700 shares, the short-interest ratio is presently 1.8 days. Approximately 6.4% of the shares of the company are short sold.

Analyst Ratings Changes

Several research firms recently issued reports on CTXR. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Citius Pharmaceuticals in a research report on Tuesday, November 12th. D. Boral Capital restated a “buy” rating and set a $9.00 price objective on shares of Citius Pharmaceuticals in a research note on Tuesday.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of CTXR. Tower Research Capital LLC TRC grew its stake in shares of Citius Pharmaceuticals by 103.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,212 shares of the company’s stock worth $33,000 after purchasing an additional 4,168 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Citius Pharmaceuticals in the third quarter worth $47,000. Virtu Financial LLC bought a new position in shares of Citius Pharmaceuticals in the third quarter worth $50,000. Miller Investment Management LP grew its stake in shares of Citius Pharmaceuticals by 99.3% in the third quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock worth $50,000 after purchasing an additional 49,640 shares in the last quarter. Finally, Fisher Asset Management LLC bought a new position in shares of Citius Pharmaceuticals in the fourth quarter worth $51,000. Institutional investors own 16.88% of the company’s stock.

Citius Pharmaceuticals Trading Down 8.0 %

CTXR traded down $0.22 during trading on Tuesday, reaching $2.48. 152,421 shares of the company were exchanged, compared to its average volume of 102,549. The stock has a market cap of $21.26 million, a P/E ratio of -0.41 and a beta of 1.28. The firm has a 50 day moving average of $3.14 and a 200 day moving average of $8.36. Citius Pharmaceuticals has a 52 week low of $2.42 and a 52 week high of $26.75.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings data on Friday, February 14th. The company reported ($1.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.05). As a group, analysts forecast that Citius Pharmaceuticals will post -4.5 earnings per share for the current fiscal year.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.